

| Title | External validation of The Paddington International Virtual Electronic Chromoendoscopy Score as a good endoscopic score to define mucosal healing and predict long-term clinical outcomes in ulcerative colitis |
|--------------------------------|--|
| Authors | Ruan, Ge Chong;Jin, Xin;Zhou, Wei Xun;You Y;Iacucci, Marietta;Ghosh, Subrata;Gui, Xian Yong;Li, Ji;Qian, Jia Ming |
| Publication date | 2022-09-19 |
| Original Citation | Ruan, G.C., Jin, X., Zhou, W.X., You, Y., Iacucci, M., Ghosh, S., Gui, X.Y., Li, J. and Qian, J.M. (2022) 'External validation of the paddington international virtual electronic chromoendoscopy score as a good endoscopic score to define mucosal healing and predict long#term clinical outcomes in ulcerative colitis', Journal of Digestive Diseases, pp. 1751-2980.13126. doi: 10.1111/1751-2980.13126 |
| Type of publication | Article (peer-reviewed) |
| Link to publisher's version | https://doi.org/10.1111/1751-2980.13126 - 10.1111/1751-2980.13126 |
| Rights | © 2022 Wiley. This is the peer reviewed version of the following article. (2022), External Validation of The Paddington International Virtual Electronic Chromoendoscopy Score As A Good Endoscopic Score to Define Mucosal Healing and Predict Long-term Clinical Outcomes in Ulcerative Colitis. J Dig Dis. Accepted Author Manuscript, which has been published in final form at https:// doi.org/10.1111/1751-2980.13126. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley's version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. |

https://hdl.handle.net/10468/13710



University College Cork, Ireland Coláiste na hOllscoile Corcaigh

/ 13

External Validation of The Paddington International Virtual Electronic Chromoendoscopy Score As A Good Endoscopic Score to Define Mucosal Healing and Predict Long-term Clinical Outcomes in Ulcerative Colitis

Running title: PICaSSO in Ulcerative Colitis

Ge Chong RUAN¹, Xin JIN¹, Wei Xun ZHOU², Yan YOU², Marietta IACUCCI³, Subrata GHOSH⁴, Xian Yong GUI⁵, Ji LI¹, Jia Ming QIAN¹

Affiliation:

- Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland.
- 5. Department of Pathology, School of Medicine, University of Washington, Seattle,
 - WA, United States

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/1751-2980.13126

Author's contributions:

Ge Chong RUAN and Xin JIN, sharing the first authorship, contributed to collection of data, statistical analysis and manuscript writing and editing.

Wei Xun ZHOU and Yan YOU contributed to the histological scores and manuscript editing.

Marietta IACUCCI, Subrata GHOSH and Xian Yong GUI contributed to the design of the study, manuscript editing and intellectual review.

Ji LI and Jia Ming QIAN, sharing the correspondence authorship, contributed to funding support, study design, patient recruitment, data collection, manuscript editing and made the decision to publish.

All author approved the final version of the manuscript for submission.

Corresponding author:

Ji LI, Email: liji0235@pumch.cn. Facsimile number: 86-10-69155019. Telephone number: 86-10-6915501. Postal address: Department of Gastroenterology, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing. Jia Ming QIAN, Email: qianjiaming1957@126.com. Postal address: Department of Gastroenterology, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing. **Aims:** To define endoscopic and histological remission in ulcerative colitis accurately, several score systems have been established. A novel Paddington International Virtual ChromoendoScopy ScOre (PICaSSO) virtual electronic chromoendoscopy (VEC) was recently developed, validated, and reproduced to assess inflammation grade and predict prognosis. We externally verified and validated the clinical value of the PICaSSO score in UC patients.

Methods: This prospective study enrolled 63 UC patients. The Mayo Endoscopic Score (MES), UC Endoscopic Index of Severity (UCEIS), and PICaSSO score were adopted for endoscopic evaluation. All biopsies were scored using the Robarts Histological Index (RHI), Nancy Histological Index (NHI), and Extent, Chronicity, Activity, and additional findings (ECAP). Patients with an endoscopic MES of 0-1 at baseline were followed up with the median time of 23.5 months.

Results: PICaSSO was strongly correlated with other endoscopic and histological scores. PICaSSO \leq 3 had advantages in assessing histological remission (HR), with the highest accuracy of 88.9% for ECAP-HR. Relapse-free survival rates were significantly different between patients with MES 0 and MES 1 and patients with PICaSSO \leq 3 vs>3 (*P* = 0.010 and 0.018, respectively).

Conclusions: PICaSSO was externally validated with strong correlations with other endoscopic and histopathologic scoring systems in UC, and PICaSSO-ER might potentially predict the better long-term clinical outcomes in UC patients.

Keywords: Clinical Outcomes; Endoscopic Remission; Histological Remission; Ulcerative Colitis; Virtual Electronic Chromoendoscopy

Ulcerative colitis (UC) is an inflammatory immunologic disorder involving the colon and rectum characterized by relapsing superficial mucosal inflammation.¹ The diagnosis of UC is based on clinical symptoms, endoscopic evaluation and histological Accepted Articl analysis.² Many scoring systems in UC are currently available for the evaluation of disease activity, including the Truelove-Witts severity score,³ Mayo Clinic Score,⁴ and UC Endoscopic Index of Severity (UCEIS).⁵ With the evolution of the treatment target from clinical remission to mucosal healing (MH), the assessment of endoscopic remission or histological remission (ER and HR) has received much more attention. Endoscopic findings are included in the Mayo score and defined as the Mayo Endoscopic Subscore (MES),⁶ which is primarily based on findings under white light. MES 0-1 is defined mainly as ER; however, many studies have indicated a totally different prognosis between patients with MES 0 and MES 1, and even in patients with MES 0.^{7,8} On account of this point, the STRIDE (Selecting Therapeutic Targets in Inflammatory Bowel Disease)-II has defined complete endoscopic healing as MES = 0, or UCEIS <1, associated with better outcomes.⁹ However, endoscopy do not necessarily distinguish mild and quiescent diseases,

and there is a growing support for histological assessment for microscopic activity.⁷ A recent study on endpoints of ustekinumab, showed that endoscopic improvement defined by MES in combination with HR outperformed in predicting inflammatory activity than endoscopic or histological assessment individually.⁸ Whether double

remission (DR), combined endo-histological remission, exactly have additional impact on outcomes has not been validated.

Meanwhile, as precision medicine develops, modern imaging-advanced instruments have greatly improved the detection of subtle mucosal details and have been recommended for assessment by the latest European Society of Gastrointestinal Endoscopy Guideline.^{10, 11, 12, 13} With advanced techniques, ER is getting closer to HR.¹⁴ Experts have gradually recommended virtual electronic chromoendoscopy (VEC) as a better alternative, reducing the gap between endoscopic and histological assessment.¹⁵ Recently, a novel VEC score, the Paddington International virtual chromoendoScopy ScOre (PICaSSO), was developed, combining the mucosal architecture under white light and vascular architecture under VEC.¹⁶ It was strongly correlated with the MES and UCEIS and many histological indices, such as the Nancy Histological Index (NHI),¹⁷ Robarts Histological Index (RHI),¹⁸ Geboes score,¹⁹ and Extent, Chronicity, Activity, Plus additional findings (ECAP).²⁰ It had a good interobserver agreement and PICaSSO ≤3 had accurate predictive potential for 6-month and 12-month remission in an international multicenter study.²¹ Furthermore, it proved good reproducibility and could be applied to all VEC platforms.²²

This prospective observational study aimed to investigate the correlation between the PICaSSO score and other endoscopic or histological scores and compare their diagnostic performance to predict ER and HR in a new cohort of patients. Furthermore, we evaluated relapse-free survival in patients with an MES of 0-1 at baseline and explored the predictive value of PICaSSO-ER and other ERs/HRs. And we investigated the performance of DR in predicting outcomes, compared with non-DR (NDR).

Methods

Patient Cohort and Enrollment

A prospective open cohort study was performed at Peking Union Medical College Hospital. All eligible adult patients met the inclusion criteria: 1) diagnosed as UC according to the consensus;²³ 2) accepted colonoscopy procedures between June 2018 and October 2019; 3) offered informed consent to participate in the study and agreed to be followed up. Exclusion criteria included inability to provide consent or refusal of follow-up, pregnancy or breastfeeding, Boston bowel preparation score \geq 4 during colonoscopy, failure of cecal intubation, contraindication or intolerance of colonoscopy. Patients were also excluded if they had Crohn's disease, unclassified IBD, ischemic colitis, infectious colitis, etc. The flowchart of the study is shown in Figure 1.

Study Variables at Baseline

Data at the time of index colonoscopy were collected, including demographics, Montreal classification, laboratory tests, endoscopic assessments, histopathologic features, and medications. Clinical disease activity status was categorized as remission or mild, moderate, or severe disease activity based on the Mayo total score (0-2 remission, 3-5 mild, 6-10 moderate, 11-12 severe)⁴. Disease extent was defined according to the Montreal Classification and categorised as proctitis (E1), left-sided colitis (E2), and extensive colitis (E3)¹⁶.

Endoscopic assessment

All colonoscopies were performed by one expert gastroenterologist (JL), who was well trained and familiar with VEC. All patients underwent polyethylene glycol-based bowel preparation prior to their colonoscopy. Colonoscopies (EC-3890Fi and EC38i10F) were assessed using an HD Pentax (Tokyo, Japan) EPK-i7000 before and after Oct 2018, and three modes: iScan1, iScan2 and iScan3, were simply switched in realtime with the button of the handpiece of the endoscope, whose standardized settings were reported recently²¹.

During withdrawal, the endoscopist collected targeted images and took at least two biopsies from the most inflamed lesions macroscopically or the representative sites at the rectum or sigmoid if there were no inflamed lesions macroscopically. After the colonoscopy, the endoscopist evaluated the images captured for the MES and UCEIS scores under white light and then for the PICaSSO score with VEC (Figure 2). For individual endoscopic severity scores, results were recorded in the form of each item, and then summed up by computer calculation systems, blinded to estimators. Details of the MES, UCEIS and PICaSSO scores are shown in Supplemental Tables 1-3. The definition of ER was MES 0-1, UCEIS ≤ 1 , or PICASSO $\leq 3.5,6,21,24$

Histological assessment

Biopsies were prepared in formalin and then processed via routine protocols into hematoxylin-eosin-stained glass slides. Each slide was scored using the NHI, RHI, and ECAP, recording concrete items also, by one expert gastrointestinal pathologist (WXZ) who was blinded to the endoscopic scores. For NHI, three key histological components were assessed, including acute inflammatory cell infiltration, chronic inflammatory cell infiltration and ulceration. Next, RHI focused on four histological markers consisting of the presence of neutrophils in the lamina propria or epithelium, chronic inflammatory cell infiltrate, and erosions or ulceration. ECAP contains comprehensive items: 1) extent of mucosal inflammation; 2) chronicity; 3) activity; and 4) plus other additional findings (e.g. eosinophilia and lymphoid follicles). The definition of HR was RHI \leq 3 (with absence of neutrophils), NHI \leq 1 or ECAP <4.^{5,17,18,20,25}

Long-term follow-up

All the patients with an MES of 0-1 at baseline accepted regular face-to-face or telephone interviews. UC relapse was defined as an increased number of bowel

/ 38

movement and/or the occurrence of blood in stool, which caused clinical specified outcomes. Clinical specified outcomes included UC relapse-related hospitalisation or colectomy, and initiation or enhancement in medical therapy, including corticosteroids, immunomodulators and biologics.

Primary and secondary outcomes

The primary outcome was to systemically evaluate the correlation between several endoscopic and histological scores.

The secondary outcomes were as follows:

- To evaluate the potential predictive prognosis of each ER or HR for clinical relapse.
- (2) To compare the diagnostic performance of three endoscopic scores to predict HR.

Statistical analysis

The mean \pm standard deviation (SD) was estimated for normally distributed continuous variables, and *Student's t-test* was used to analyze the significant differences between the two groups. Continuous nonnormally distributed data were expressed as the median (interquartile range), and a nonparametric test was used for two-group comparisons. Categorical data were reported as counts and proportions, and the difference was assessed by *Fisher's* exact test. Pearson's test was conducted to clarify the correlation between the three histological scores. Correlations among the three endoscopic scores and histological scores were investigated using Spearman's correlation coefficients. A very strong correlation was defined as 0.80 to 1.0, a strong correlation as 0.60 to 0.79, a moderate correlation as 0.40 to 0.59, and a weak correlation as 0.20 to 0.39. The agreement between certain ERs and HRs was calculated as the kappa coefficient.

Kaplan–Meier survival curves for patients with survival free of clinical relapse were developed, and the log-rank test was used to assess significance. A *P* value of less than 0.05 was considered statistically significant. Statistical analyses were performed using IBM GraphPad Prism 9.

Ethical considerations

This study was approved by the Ethics Committee of PUMCH (No. ZS-1748). Patients enrolled in the study all gave written informed consent. The anonymity of all patients was safely protected.

Results

Baseline Demographics and Clinical Characteristics of UC Patients

A total of 63 UC patients were finally enrolled in the study, and their baseline characteristics were shown in Table 1. The mean age was 40.9±13.8 years, and 50.8%

/ 38

were male. The prevalence of the disease extent was 17.5% for E1, 22.2% for E2, and 60.3% for E3. The disease statuses of 27 (42.9%), 21 (33.3%) and 15 (23.8%) patients were remission, mild and moderate active disease, respectively.

Correlations among different endoscopic scores and histological scores

Significant correlations among the three endoscopic scores were found. PICaSSO showed a very strong correlation with MES score (r = 0.916, P < 0.01) and UCEIS score (r = 0.904, P < 0.01). The UCEIS correlated very strongly with the MES (r = 0.887, P < 0.01).

Meanwhile, these very strong correlations can also be seen among ECAP, RHI and NHI, with Pearson coefficients ranging from 0.843 to 0.876.

Spearman correlation coefficients between endoscopic scores and histological scores are presented in Table 2. A strong correlation between PICaSSO and ECAP (r = 0.781, P < 0.01), RHI (r = 0.658, P < 0.01), and NHI (r = 0.661, P < 0.01) was notable. MES with ECAP was the only group that correlated very strongly (r = 0.808, P < 0.01), and MES was strongly correlated with RHI (r = 0.720, P < 0.01) and NHI (r = 0.723, P < 0.01). The UCEIS also displayed a strong correlation with histological scores. For histological scores, ECAP seemed to present better correlations with all endoscopic scores.

Accuracy of Endoscopic scores in Histological-Remission prediction

The diagnostic performances of ER to HR are shown with sensitivity, specificity, and accuracy in Table 3. Generally, PICaSSO-ER performed better in assessing ECAP-HR and NHI-HR than RHI-HR. PICaSSO-ER was highly likely to reflect HR, with the highest accuracy of 88.9% for ECAP-HR, 85.7% for NHI-HR, and 81.0% for RHI-HR. The UCEIS-ER assessing HR showed an accuracy of 84.1% for ECAP-HR, 84.1% for NHI-HR, and 82.5% for RHI-HR. MES-ER had lower accuracy in predicting HR than UCEIS-ER and PICaSSO-ER, especially for ECAP-HR, with the lowest accuracy of 71.4%.

The predictive potential of each ER or HR for the long-term prognosis of UC patients with MES 0-1 at baseline

Twenty-six UC patients with an MES of 0-1 completed the median of 23.5 (16.25, 27.75) months of follow-up. At baseline, 7 of 26 (26.9%) were on topical therapies, 19 (73.1%) were treated with ASA, 4 (15.4%) with TCM, 1 (3.8%) with corticosteroids, 1 (3.8%) with biologics and 2 (7.7%) with immunomodulators. Nine (34.6%) patients displayed specified outcomes in therapy. The median time of specified outcomes were 17 (10, 19) months, calculated including only patients who experienced a relapse during the study period. The shortest relapse duration was 4 months in a patient on suppository ASA therapy.

Figure 3 presents the Kaplan–Meier curves for relapse-free survival of UC patients with ER versus non-ER and HR versus non-HR. The results of the log-rank test showed significantly increased survival rates in the MES = 0 versus MES = 1 (HR = 0.113; 95% CI, 0.030-0.417; P = 0.010) and PICaSSO ≤ 3 versus PICaSSO ≥ 3 (HR = 0.189; 95% CI, 0.050-0.718; P = 0.018) groups. However, for patients with UCEIS ≤ 1 , the specified clinical outcome events were not significantly different from UCEIS ≥ 1 (P = 0.104). Analysis showed that the differences in HR defined by histology scores were not significant (RHI ≤ 3 vs RHI ≥ 3 , P = 0.730; NHI ≤ 1 vs NHI ≥ 1 , P = 0.406), except for ECAP, which had a slightly larger difference (ECAP ≤ 4 vs ECAP ≥ 4 , P = 0.067). A further analysis showed that MES 0 combined with ECAP ≤ 4 was significantly different in predicting outcomes compared with NDR (Log Rank P = 0.030). There was no significant difference of PICaSSO-ER combined with ECAP-HR, RHI-HR or NHI-HR compared with NDR (P = 0.067, 0.130 and 0.237, respectively).

Discussion

As a novel endoscopic score, PICaSSO has been developed and validated as a potential endoscopic score because of its predictive value of ER and HR and high interobserver agreement²¹. In account of the strict inclusion criteria and only 1-year follow-up in the previous multi-center study, it still needs external validation in routine clinical practice. In this prospective study, we revealed the strong correlation among the

endoscopic scores (PICaSSO, MES, and UCEIS), as well as histological scores (ECAP, RHI and NHI). We found the accuracy of PICsSSO-ER for the prediction of HR was comparable with widely-used MES-ER and UCEIS-ER, and showed the favorable value in predicting ECAR-HR. Finally, PICaSSO-ER individually could predict better relapse-free survival during the median 2-year follow-up in UC patients with MES 0-1 at baseline.

Unlike Crohn's disease, most studies confirmed the strong correlation between endoscopic and histological scores in UC patients.²⁶ However, the cutoff values of MES-ER and UCEIS-ER have not yet been confirmed, and there is an absence of a validated definition of MH.^{27,28,29} In general, ER contains the absence of friability, blood, erosions and ulcers in all visualized segments in the colorectal mucosa.^{30,31} Routine endoscopies can evaluate the majority of UCs at the active phase, but do not necessarily reflect quiescent microscopic disease, especially when MES 0-1 are considered together as the endpoint.³² The interobserver agreement rates of endoscopic diagnosis are not stable. In Kanazawa's study, the parameter "absent vascular pattern" in MES displayed low interobserver reliability among IBD experts and nonexperts.³³ Meanwhile for better detection of residual inflammation, histological assessment might indicate complete resolution better.²⁶ Using VEC, vascular pattern is not absent but visible with abnormalities as defined in PICaSSO score. Our study, designed as a single operator based on commonly used criteria, showed PICaSSO-ER had the best diagnostic performances of ECAP-ER. In another similar study, the PICaSSO score also showed superior performance in assessing NHI-HR and RHI-HR.²¹

Before the announcement of STRIDE-II, MES 0-1 is identified as mucosal remission in routine clinical practice.³⁴ However, it has been indicated that MES \leq 1 might not be an ideal indicator recently. Our results also showed a significant difference in relapse-free survival between patients with MES 0 and MES 1, consistent with several other studies.^{35,36} Meanwhile, it is noteworthy that our study suggested that PICaSSO \leq 3 individually or combined with ECAP \leq 4 was more likely to predict preferable outcomes, which has shown the promising potential as the endpoint or target of medication.

It is still undetermined whether ER combined with HR could have more advantages to predict the long-term outcomes. Christensen. et al. proposed "histological normalization", which could better predict good outcomes than histological quiescence and ER alone.³⁷ A prior meta-analysis also indicated the incremental benefit of achieving double remission based on long-term duration of follow-up in UC patients with MES 0.³⁸ More specifically, we found that MES 0 combined with ECAP-HR was associated with a substantially better prognosis than non-double remission UC. In account of the very limited number of MES 0, whether this more rigorous endpoint, double remission, is supposed to replace clinical routine target, it still needs more multicenter comparative studies involving multiple combos of ER and HR in future. However, the difference of PICaSSO-ER combined with HR didn't reach statistical significance, which was consistent with the previous multi-center study.³⁹ Perhaps it strongly suggested that PICaSSO-ER was sufficient to distinguish different prognosis of mild or quiescent UC patients(MES 0/1), while MES alone had limited capability.

The highlights of this study are as follows: first, we used the VEC and incorporated the recently validated PICaSSO into the design. VECs are now available on most endoscopies in the clinic and display much subtler images than conventional white light.⁴⁰ Second, in contrast to the previously published multicenter study, the inclusion criteria of this study are not strict and appropriate for real-world clinical practice. Biopsies were taken and evaluated in the most inflamed lesions macroscopically, which are also efficiently conducted. Finally, this study had a median 2-year long-term follow-up, the longest for PICaSSO, which could be useful to determine changes in outcomes along the natural course of the disease.

This study had some relevant limitations. First, in the case of the single-centre study, the number of participants was limited, especially for UC patients with an MES of 0-1, probably due to the COVID-19 pandemic and the desire for unnecessary colonoscopy in patients with MES-ER. Meanwhile, for the long-term follow-up, the telephone interview, an pivotal approach to collect information from the patients in account of normalization of the epidemic. However, it was still a powerful research, because our team were composed of IBD specialists, which enabled to guarantee the quality of enrollment and crucial endoscopic and histological assessment. Second, the exact threshold of recently developed scores in our study needs further examination,

especially when the endoscopic score and histological score were all recorded by one endoscopist and one pathologist individually. Fortunately, it is noteworthy that a brief training module has been established and non-expert endoscopists and a trainee can present the same performance as an experienced endoscopist after a short learning for the PICaSSO score.²² Third, as various medications were prescribed by former physicians, may alter the distribution and nature of mucosal changes, further comprehensive multivariate analyses are needed, such as therapy strategies, dosage regimens and administrations. Finally, many new scores have continued to emerge: Toronto IBD Global Endoscopic Reporting score,⁴¹ PICaSSO Histologic Remission Index,⁴² Capsule Scoring of Ulcerative Colitis,⁴³ and The Mucosal Analysis of Inflammatory Gravity by i-scan TE-c Image.⁴⁴ These scores are not involved and compared with PICaSSO in this study, which comparative studies will be conducted in future.

In conclusion, PICaSSO was externally validated with strong correlations with other endoscopic and histopathologic scoring systems in UC, and PICaSSO-ER might potentially predict the better long-term clinical outcomes in UC patients, which added more evidence about the predict value of PICaSSO-ER.

Acknowledgements: This work was supported by grants from Nonprofit Central Research Institute Fund of Chinese Academy of Medical Sciences (Nos.

2019XK320043 and 3332018012), Health Research & Special Projects Grant of China (Nos.201002020 and Nos.201502005).

Conflicts of interest: All authors declared that there were no conflicts of interest.

References

 Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am 2020;49:643-654.

2. Kaenkumchorn T, Wahbeh G. Ulcerative colitis: making the diagnosis. Gastroenterol Clin North Am 2020;49:655-669.

3. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-1048.

 Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:1649-1651.

5. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity(UCEIS).Gut 2012;61:535-542.

6. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629.

7. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with Ulcerative Colitis (VARSITY). Gastroenterology 2021;161:1156-1167.

8. Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis. Gastroenterology 2020;159:2052-2064.

9. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A, International organization for the study of IBD. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160:1570-1583.

10. Tontini GE, Pastorelli L, Ishaq S, Neumann H. Advances in endoscopic imaging in ulcerative colitis. Expert Rev Gastroenterol Hepatol 2015;9:1393-1405.

11. Tontini GE, Rath T, Neumann H. Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases. World J Gastroenterol 2016;22:1246-1259.

12. Pouw RE, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czakó L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-Ribeiro M, Vieth M, van Hooft JE. Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1261-1273.

13. Iacucci M, Kiesslich R, Gui X, et al. Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis. Endoscopy. 2017; 49: 553-559.

14. Iacucci M, Kiesslich R, Gui X, Panaccione R, Heatherington J, Akinola O, Ghosh S. Ultra-high magnification endocytoscopy and molecular markers . Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis for defining endoscopic and histologic remission in ulcerative colitis-an exploratory study to define deep remission. Inflamm Bowel Dis 2021;27:1719-1730.

15. Parigi TL, Mastrorocco E, Da Rio L, Allocca M, D'Amico F, Zilli A, Fiorino G, Danese S, Furfaro F. Evolution and new horizons of endoscopy in inflammatory bowel diseases. J Clin Med 2022;11:872.

16. Iacucci M, Daperno M, Lazarev M, Arsenascu R, Tontini GE, Akinola O, Gui XS, Villanacci V, Goetz M, Lowerison M, Lethebe BC, Vecchi M, Neumann H, Ghosh S, Bisschops R, Kiesslich R. Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. Gastrointest Endosc 2017;86:1118-1127.

17. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L.
Development and validation of the Nancy histological index for UC. Gut 2017;66:43-49.

18. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. Development and validation of a histological index for UC. Gut 2017;66:50-58.

19. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-409.

20. Iacucci M, Fort Gasia M, Hassan C, Panaccione R, Kaplan GG, Ghosh S, Gui X. Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. Endoscopy 2015;47:726-734. 21. Iacucci M, Smith SCL, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Nardone OM, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S. An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in ulcerative colitis. Gastroenterol 2021;160:1558-1569.

22. Cannatelli R, Bazarova A, Furfaro F, Parigi TL, Zardo D, Nardone OM, Spaggiari P, Villanacci V, Cadei M, Labarile N, Smith SCL, Danese S, Ghosh S, Iacucci M. Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis using multiple endoscopic platforms: a prospective multicenter international study (with video). Gastrointest Endosc 2022;96:73-83.

23. Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis. 2021; 22: 298-317.

24. Di Ruscio M, Variola A, Vernia F, Lunardi G, Castelli P, Bocus P, Geccherle A. Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in predicting patients' response to biological therapy and the need for colectomy. Digestion 2021;102:534-545. 25. Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL. Correlation between endoscopic and histological activity in ulcerative colitis using validated indices. J Crohns Colitis 2018;12:1151-1157.

26. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014;8:1582-1597.

27. Shah J, Dutta U, Das A, Sharma V, Mandavdhare H, Sharma P, Kalsi D, Popli P, Kochhar R. Relationship between Mayo endoscopic score and histological scores in ulcerative Colitis: A prospective study. JGH Open 2019;4:382-386.

28. De Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA. Validation and investigation of the operating characteristics of the ulcerative colitis endoscopic index of severity. Inflamm Bowel Dis 2019;25:937-944.

29. Iacucci M, Ghosh S. Mucosal Healing - How deep is enough? Dig Dis 2016;34:160-164.

30. Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther 2017;45:801-813. 31. Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-1023.

32. Ando T, Nishio Y, Watanabe O, Takahashi H, Maeda O, Ishiguro K, Ishikawa D, Ohmiya N, Niwa Y, Goto H. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol 2008;14:2133-2138.

33. Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of endoscopic evaluation reliability for ulcerative colitis in histological remission. Healthcare (Basel) 2021;9:1405.

34. Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL, Panés J, Rimola J, Louis E. Scientific committee of the european crohn's and colitis organization. Results of the 2nd part scientific workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5:484-498.

35. Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal healing in ulcerative colitis--When zero is better. J Crohns Colitis 2016;10:20-25.

36. Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, CicconeA, Vernia F, Latella G. Systematic review and meta-analysis: the advantage of

37. Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol 2017;15:1557-1564.

38. Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: A systematic review and meta-analysis.
Gastroenterology 2020;159:1262-1275.

39. Nardone OM, Bazarova A, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Smith SCL, Shivaji UN, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S, Iacucci M. PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis. United European Gastroenterol J 2022;10:147-159.

40. Meserve J, Singh S. Pathologist, meet Picasso! Virtual chromoendoscopy for
detecting histologic remission in ulcerative colitis. Gastroenterology 2021;160:14691472.

41. Zittan E, Steinhart AH, Aran H, Milgrom R, Gralnek IM, Zelber-Sagi S, Silverberg MS. The Toronto Ibd Global Endoscopic Reporting (Tiger) score: A single, easy to use endoscopic score for both crohn's disease and ulcerative colitis patients. J Crohns Colitis 2022;16:544-553.

42. Gui X, Bazarova A, Del Amor R, Vieth M, de Hertogh G, Villanacci V, Zardo D, Parigi TL, Røyset ES, Shivaji UN, Monica MAT, Mandelli G, Bhandari P, Danese S, Ferraz JG, Hayee B, Lazarev M, Parra-Blanco A, Pastorelli L, Panaccione R, Rath T, Tontini GE, Kiesslich R, Bisschops R, Grisan E, Naranjo V, Ghosh S, Iacucci M. PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. Gut 2022;71:889-898.

43. Hosoe N, Nakano M, Takeuchi K, Endo Y, Matsuoka K, Abe T, Omori T,
Hayashida M, Kobayashi T, Yoshida A, Mizuno S, Nakazato Y, Naganuma M, Kanai T, Watanabe M, Ueno F, Suzuki Y, Hibi T, Ogata H. Establishment of a novel scoring system for colon capsule endoscopy to assess the severity of ulcerative colitis-capsule scoring of ulcerative colitis. Inflamm Bowel Dis 2018;24:2641-2647.

44. Honzawa Y, Matsuura M, Higuchi H, Sakurai T, Seno H, Nakase H. A novel endoscopic imaging system for quantitative evaluation of colonic mucosal inflammation in patients with quiescent ulcerative colitis. Endosc Int Open 2020;8:E41-E49.

Table 1. Baseline demographics and clinical characteristics of Patients

| Characteristics | Patients (n=63) | | |
|---|-----------------|--|--|
| Gender Male n (%) | 32 (50.8%) | | |
| Age at enrollment, y (mean \pm SD) | 40.9 ± 13.8 | | |
| Disease extension | | | |
| E1 | 11 (17.5%) | | |
| E2 | 14 (22.2%) | | |
| E3 | 38 (60.3%) | | |
| Clinical disease activity based on Mayo total s | score | | |
| Remission | 27 (42.9%) | | |
| Mild | 21 (33.3%) | | |
| Moderate | 15 (23.8%) | | |
| Endoscopic activity | | | |
| Mayo Endoscopic Subscore n (%) | | | |
| MES = 0 | 13 (20.6%) | | |
| MES = 1 | 13 (20.6%) | | |
| MES = 2 or 3 | 37 (58.7%) | | |

]

| UCEIS n (%) | |
|-----------------------|------------|
| Remission (<1) | 18 (28.6%) |
| Active (>1) | 45 (71.4%) |
| PICASSO n (%) | |
| Remission (\leq 3) | 15 (23.8%) |
| Active (>3) | 48 (76.2%) |
| Histological activity | |
| ECAP n (%) | |
| Remission (≤4) | 8 (12.7%) |
| Active (>4) | 55 (87.3%) |
| RHI n (%) | |
| Remission (≤3) | 15 (23.8%) |
| Active (>4) | 48 (76.2%) |
| NHI n (%) | |
| Remission (≤1) | 16 (25.4%) |
| Active (>1) | 47 (74.6%) |
| Therapy at baseline | |
| No treatment | 1 (1.6%) |

| | Corticostero |
|---|--------------------------|
| | Immunomod |
| | Biologics |
| 5 | TCM |
| | |
| | |
| | Abbreviations: MES, Ma |
| | Endoscopic Index of Sev |
| | ChromoendoScopy ScOr |
| | findings'; RHI, Robarts |
| 0 | aminosalicylic acid; TCM |
| | |

Accept

| ASA † | 49 (77.8%) |
|------------------|------------|
| Corticosteroids | 5 (7.9%) |
| Immunomodulators | 5 (7.9%) |
| Biologics | 2 (3.1%) |
| TCM | 6 (9.5%) |

Abbreviations: MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; PICaSSO, Paddington International Virtual ChromoendoScopy ScOre; ECAP, 'Extension, Chronicity, Activity, Plus additional findings'; RHI, Robarts Histological Index; NHI, Nancy Histological Index. ASA, aminosalicylic acid; TCM, traditional Chinese medicine.

[†]Among patients who were treated with ASA, 43 received oral ASA,12 suppository, 4 enema.

| ECAP | RHI | NHI |
|---------|---------------------------------------|--|
| | | |
| 0.808** | 0.720** | 0.723** |
| | | |
| 0.775** | 0.699** | 0.694** |
| | | |
| 0.781** | 0.658** | 0.661** |
| | ECAP 0.808** 0.775** 0.781** | ECAP RHI 0.808** 0.720** 0.775** 0.699** 0.781** 0.658** |

Abbreviations: MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; PICaSSO, Paddington International Virtual ChromoendoScopy ScOre; ECAP, 'Extension, Chronicity, Activity, Plus additional findings'; RHI, Robarts Histological Index; NHI, Nancy Histological Index.

‡ Spearman correlation coefficients were used to estimate correlation. **P < 0.01

Table 3. Sensitivity, Specificity and Accuracy of Endoscopic Remission in Predicting

| | H | listo | logical | Remission |
|--|---|-------|---------|-----------|
|--|---|-------|---------|-----------|

| | ECAP-HR | RHI-HR | NHI-HR | |
|-------------|---------|--------|--------|--|
| | | | | |
| MES -ER | | | | |
| sensitivity | 30.8% | 57.7% | 61.5% | |
| specificity | 100% | 97.3% | 100% | |
| accuracy | 71.4% | 79.4% | 84.1% | |
| UCEIS-ER | | | | |
| | | | | |
| sensitivity | 44.4% | 61.1% | 66.7% | |
| specificity | 100% | 91.1% | 91.1% | |
| accuracy | 84.1% | 82.5% | 84.1% | |
| PICASSO-ER | | | | |
| | | | | |
| sensitivity | 53.3% | 60.0% | 73.3% | |
| specificity | 100% | 87.5% | 89.6% | |
| | | | | |

81.0%

85.7%

Abbreviations: MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis

Endoscopic Index of Severity; PICaSSO, Paddington International Virtual

ChromoendoScopy ScOre. HR, histological remission; ER, endoscopic remission

Figure Legends

Figure 1. Flow chart for the study process.

Figure 2. The representative figures assessed by white-light, iSCAN-2 and iSCAN-3. A-C showed the diffuse ulcer and intramucosal bleeding. D-F showed the diffuse erosion and intramucosal bleeding. G-I showed the mild microerosion with roundish and crowded-tortuous vessels. J-L showed normal mucosal and vascular pattern.

Figure 3. Kaplan-Meier curves for relapse-free survival in patients. (A) MES = 0 vs MES = 1; (B) PICaSSO \leq 3 vs PICaSSO >3; (C) UCEIS \leq 1 vs UCEIS >1; (D) ECAP \leq 4 vs ECAP >4; (E) RHI \leq 3 vs RHI >3; (F) NHI \leq 1 vs NHI >1; (G) PICaSSO-ER + RHI-HR vs NDR; (H) PICaSSO-ER + ECAP-HR vs NDR; (I) PICaSSO-ER + NHI-HR vs NDR; (J) MES-ER + RHI-HR vs NDR; (K) MES-ER + ECAP-HR vs NDR; (L) MES-ER + NHI-HR vs NDR.

Abbreviations: MES, Mayo Endoscopic Subscore; UCEIS, Ulcerative Colitis Endoscopic Index of Severity; PICaSSO, Paddington International Virtual ChromoendoScopy ScOre; ECAP, 'Extension, Chronicity, Activity, Plus additional findings'; RHI, Robarts Histological Index; NHI, Nancy Histological Index.









rotected by copyright. All























Hazard ratio = 0.295 (0.080-0.1.091)

Time (month)

This article is protected by copyright. All rights reserved.

PN-DR PN-NDR • • • • • - - • • • • •



Hazard ratio = 0.273 (0.067-1.114)

This article is protected by copyright. All rights reserved.

Time (month)

* • • • • • • • • • • • • • • •

NR-NDR • • • • • • • • • • •

Time (month)

•••••

This article is protected by copyright. All rights reserved.

ME-NDR • • • • • • • • • • •

Hazard ratio = 0.173 (0.046-0.648)

This article is protected by copyright. All rights reserved.

Time (month)

•••••

MN-NDR

• • • • • • • • • • • •